The June 2020 issue of Pharmafocus is available to read free online now!
pharmafile | May 27, 2020 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | COVID-19, Vaccine, coronavirus, data management, pharma, rare disease, treatment access
The latest monthly edition of Pharmafocus, the June 2020 issue, is available to read for free online now!
The world remains in thrall to COVID-19; even as national governments try to instil some sense of control and stability enough to begin to fire their economies back up, everything is still seen through the veil of the pandemic. The life sciences industry has all of its big guns trained on one target, and day by day it pushes our knowledge of COVID-19 and how we can beat it.
Despite perhaps unprecedented R&D efforts, progress has been tentative. Moderna’s promising vaccine candidate has shown very early positive signs, while AstraZeneca and the University of Oxford press forward with their own candidate. Even though concrete efficacy data remains elusive, new research supports the idea that the immune system can mount a defence against the virus in recovered patients, providing hope for future preventative treatment efforts.
In this month’s issue, Conor Kavanagh explores how management and analysis of data could form a key column in response to the coronavirus threat, particularly through the use of contact-tracing apps, in o full-length feature piece.
In our second feature, we take a look at the impact the pandemic and national lockdowns are having on the rare disease community, particularly with regards to their ability to access the treatment and care they need. We also catch up with three previous contributors to Pharmafocus who have previously shared their patient experiences to share their stories of life in this difficult time.
Also in the issue, Deloitte’s Karen Taylor and Maria Joao Cruz reflect on the R&D productivity of the top 12 biopharma firms to see what lessons have been learned over the past decade in the space, and that means for the future.
Related Content
Gilead’s Veklury recommended by NICE for COVID-19 treatment
Gilead Sciences has announced that the National Institute of Health and Care Excellence (NICE) has …
NICE expands access to Paxlovid for 1.4 million people at risk of severe COVID-19
The National Institute for Health and Care Excellence (NICE) has announced that it has expanded …
GSK shares new data for RSV vaccine Arexvy
GSK announced positive results from its phase 3 trial which assessed the immune response and …
